Loading
Latest filing published 11 Dec 2023 for HCW Biologics Inc., €1,821. Read the official filing
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Peter Rhode in HCW Biologics Inc., where the filings describe the role as chief executive. We count 4 filings; the first trade dates from 22 July 2021 and the latest from 11 December 2023.
On the market, this insider has only ever bought: 1 purchase, €85k in total. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 3 option exercises.
The newest entry dates from 11 December 2023: an option exercise of €1,821, in HCW Biologics Inc. The clock since the last published purchase (23 July 2021) now reads 1,913 days. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations